Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Immunicum AB Announces FDA Approval to Expand Ph Ib/II trial of Cancer Drug
Immunicum AB Announces FDA Approval to Expand Ph Ib/II trial of Cancer Drug
Immunicum AB Announces FDA Approval to Expand Ph Ib/II trial of Cancer Drug
Submitted by
admin
on July 23, 2018 - 10:12am
Source:
CP Wire
News Tags:
Immunicum
clinical trials
ilixadencel
head and neck cancer
non-small cell lung cancer
gastric cancer
Headline:
Immunicum AB Announces FDA Approval to Expand Ph Ib/II trial of Cancer Drug
snippet:
Ph II study will include up to 150 patients
The study will include testing in head and neck cancer, non-small cell lung cancer and gastric and gastroesophageal junction adenocarcinoma
Overall ilixadencel is being studied in six cancer types
Immunicum has two additional immuno-oncology drugs under development
Do Not Allow Advertisers to Use My Personal information
